BR0015580A - Composições analgésicas contendo buprenorfina - Google Patents

Composições analgésicas contendo buprenorfina

Info

Publication number
BR0015580A
BR0015580A BR0015580-2A BR0015580A BR0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A
Authority
BR
Brazil
Prior art keywords
buprenorphine
compositions containing
nalmefene
naltrexone
naloxone
Prior art date
Application number
BR0015580-2A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare
Mited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare, Mited filed Critical Reckitt Benckiser Healthcare
Publication of BR0015580A publication Critical patent/BR0015580A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES ANALGéSICAS CONTENDO BUPRENORFINA ". Composição analgésica na forma de dosagem unitária parenteral, ou em uma forma de dosagem adequada para distribuição via mucosa, compreendendo uma quantidade de buprenorfina que é inferior à dose clínica necessária para alcançar alívio da dor; e uma quantidade de naloxona de modo que a relação em peso de buprenorfina para naloxona seja na faixa de 12,5:1 a 27,5:1, ou uma quantidade de naltrexona ou nalmefeno de modo que a relação em peso de buprenorfina para naltrexona ou nalmefeno seja na faixa de 12,5:1 a 22,5:1, com o que a ação analgésica da buprenorfina é potencializada pela baixa dose de naloxona, naltrexona ou nalmefeno.
BR0015580-2A 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina BR0015580A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
BR0015580A true BR0015580A (pt) 2002-07-09

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015580-2A BR0015580A (pt) 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina

Country Status (30)

Country Link
US (4) US6995169B2 (pt)
EP (1) EP1242087B1 (pt)
JP (1) JP4745576B2 (pt)
KR (1) KR100726699B1 (pt)
CN (1) CN100431543C (pt)
AR (1) AR031682A1 (pt)
AT (1) ATE262335T1 (pt)
AU (1) AU777259B2 (pt)
BR (1) BR0015580A (pt)
CA (1) CA2392013C (pt)
CO (1) CO5261517A1 (pt)
CZ (1) CZ303160B6 (pt)
DE (1) DE60009346T2 (pt)
DK (1) DK1242087T3 (pt)
ES (1) ES2214334T3 (pt)
GB (1) GB2356348B (pt)
HU (1) HU229565B1 (pt)
IL (2) IL149580A0 (pt)
MX (1) MXPA02004978A (pt)
NO (1) NO321965B1 (pt)
NZ (1) NZ519023A (pt)
PL (1) PL199727B1 (pt)
PT (1) PT1242087E (pt)
RO (1) RO121174B1 (pt)
RU (1) RU2255737C2 (pt)
SI (1) SI21025B (pt)
SK (1) SK286888B6 (pt)
TR (1) TR200400653T4 (pt)
TW (1) TW550070B (pt)
WO (1) WO2001035942A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
CA2630624C (en) * 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
JP2011521973A (ja) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
JP6210988B2 (ja) 2011-09-19 2017-10-11 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
RU2077326C1 (ru) * 1992-12-29 1997-04-20 Ярыгин Владимир Никитич Препарат для анальгезии
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP1280529A2 (en) * 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists

Also Published As

Publication number Publication date
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
CA2392013C (en) 2009-08-11
JP4745576B2 (ja) 2011-08-10
AU777259B2 (en) 2004-10-07
GB2356348B (en) 2002-02-06
WO2001035942A2 (en) 2001-05-25
ES2214334T3 (es) 2004-09-16
TR200400653T4 (tr) 2004-04-21
SK8762002A3 (en) 2002-12-03
RU2002116361A (ru) 2004-01-27
PL199727B1 (pl) 2008-10-31
WO2001035942A9 (en) 2002-11-28
NO20022330L (no) 2002-07-04
KR100726699B1 (ko) 2007-06-13
MXPA02004978A (es) 2003-01-28
SI21025B (sl) 2008-04-30
HUP0203588A3 (en) 2005-01-28
US20060058332A1 (en) 2006-03-16
US20060069113A1 (en) 2006-03-30
RO121174B1 (ro) 2007-01-30
DK1242087T3 (da) 2004-07-19
GB2356348A (en) 2001-05-23
NO20022330D0 (no) 2002-05-15
AR031682A1 (es) 2003-10-01
US20060058333A1 (en) 2006-03-16
WO2001035942A3 (en) 2002-06-13
TW550070B (en) 2003-09-01
NZ519023A (en) 2004-11-26
IL149580A (en) 2007-05-15
EP1242087B1 (en) 2004-03-24
GB0028088D0 (en) 2001-01-03
NO321965B1 (no) 2006-07-31
CN1413110A (zh) 2003-04-23
HU229565B1 (hu) 2014-02-28
CN100431543C (zh) 2008-11-12
US7402591B2 (en) 2008-07-22
DE60009346T2 (de) 2005-02-10
KR20020058022A (ko) 2002-07-12
SK286888B6 (sk) 2009-07-06
HK1055389A1 (zh) 2004-01-09
HUP0203588A2 (hu) 2003-03-28
AU1529701A (en) 2001-05-30
IL149580A0 (en) 2002-11-10
JP2003514013A (ja) 2003-04-15
CZ303160B6 (cs) 2012-05-09
CO5261517A1 (es) 2003-03-31
US6995169B2 (en) 2006-02-07
CA2392013A1 (en) 2001-05-25
EP1242087A2 (en) 2002-09-25
PL355330A1 (en) 2004-04-19
ATE262335T1 (de) 2004-04-15
RU2255737C2 (ru) 2005-07-10
PT1242087E (pt) 2004-06-30
DE60009346D1 (de) 2004-04-29

Similar Documents

Publication Publication Date Title
BR0015580A (pt) Composições analgésicas contendo buprenorfina
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR9813827A (pt) Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BR0111186A (pt) Uso de composição de celecoxib para rápido alìvio de dor
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
JP2003514013A5 (pt)
EP0871488A4 (en) ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
HK80492A (en) Pharmaceutical compositions with analgesic properties and the preparation and use thereof
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
NZ326345A (en) Composition containing diosgenin
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
HU9203022D0 (en) Pharmaceutical preparatives with upriflavone content methods for production and medical utilization of said compounds

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.